Preparation of Metabolites by Chemical Reaction: Conversion of Antipsychotic Phenothiazines to Their Sulfoxides and Tertiary

Total Page:16

File Type:pdf, Size:1020Kb

Preparation of Metabolites by Chemical Reaction: Conversion of Antipsychotic Phenothiazines to Their Sulfoxides and Tertiary 396 Journal of Health Science, 50(4) 396–406 (2004) Preparation of Metabolites N-oxides from parent drug could be confirmed when the collisional energy was decreased to 10 eV. 1H- and by Chemical Reaction: 13C-NMR spectral data confirmed the structure of the Conversion of Antipsychotic prepared mianserin N-oxide to be 2-oxide. In conclu- sion, a simple and rapid preparation method for oxide Phenothiazines to their metabolites of phenothiazines and tertiary amino cy- Sulfoxides and Tertiary clic antidepressants available as analytical standards was established. Amino Cyclic Key words —–— metabolite, chemical preparation, ox- Antidepressants ide, phenothiazine, cyclic antidepressants, mass spectros- to their N-Oxide with copy Hydrogen Peroxide Using Titanosilicate INTRODUCTION Catalyst The identification and quantification of drugs Akira Ogamo* and Mariko Fukumoto ingested into human bodies require comprehensive information covering the target drugs themselves and School of Pharmaceutical Sciences, Kitasato University, their metabolites. To carry out a quantitative analy- Shirokane 5–9–1, Minato-ku, Tokyo 108–8641, Japan sis, the standard substances of metabolites are es- (Received March 5, 2004; Accepted April 11, 2004) sential. Some important metabolites can be obtained as commercial products, but many metabolites, es- The aim of this study was to establish a prepara- pecially those of new drugs, are difficult to obtain tion method needed to analyze the metabolites of an as standard samples. These problems have been analytical procedure for antipsychotic phenothiazines solved by using experimental animals or isolated and tertiary amino cyclic antidepressants by chemical enzyme systems originating from biological mate- reaction. These drugs were oxidized to their sulfoxide rials. But defects such as low yield, high cost, and and N-oxide, respectively, with hydrogen peroxide us- lengthy preparation time have necessitated the search ing titanosilicate as the catalyst. An acidic medium for another effective method. Preparing metabolites (pH 3.0) containing 20% methanol was found to be op- timal for the preparation of phenothiazine sulfoxide, by applying a chemical reaction to target drugs may and an alkaline medium (pH 10.5) containing 50% be effective, if the reaction is specific, rapid, simple, methanol was optimal for the preparation of the N- and applicable to a broad range of organic com- oxide of tertiary amino cyclic antidepressants. Each pounds. preparative scale reaction (2 mmol) was carried out Drugs acting on the central nervous system are and the crystallized product of each oxide was ob- the main targets of analysis in emergency medicine tained. The amount of hydrogen peroxide needed to and forensic analytical toxicology. The major me- obtain the best yields of sulfoxide was 1.3–2.0 times tabolites of phenothiazine drugs in blood and urine the molar equivalent of the phenothiazines. The puri- are their corresponding sulfoxides together with the ties of the prepared crystallized product of the phe- hydroxylated form.1) Although the sulfoxides gen- nothiazine sulfoxides were good except for periciazine erally lack antipsychotic activity, they may be re- sulfoxide. The amounts of hydrogen peroxide needed sponsible for the adverse effects (e.g. cardiotoxic to obtain the best yields of N-oxide were 4–5 times the activity2,3)) associated with drug intake. Conventional molar equivalent of tertiary amino cyclic antidepres- preparation methods for phenothiazine sulfoxide sants. The purities of the crystals of each N-oxide were have been reported.4–9) The yields of these methods 99.5–100%. The characteristic mass fragment ions of are not sufficient, and the phenothiazine derivatives each prepared oxide that were distinguishable as the reported have been limited to simple structural phe- nothiazine derivatives and drugs produced at an early *To whom correspondence should be addressed: School of Phar- stage of development. maceutical Sciences, Kitasato University, Shirokane 5–9–1, Most of the cyclic antidepressants used clinically Minato-ku, Tokyo 108–8641, Japan. Tel.: +81-3-5791-6332; Fax: include a ternary amino group in their structures. +81-3-3442-1946; E-mail: [email protected] Major metabolites of these cyclic antidepressants are No. 4 397 the N-demethylated and hydroxylated forms.1) Al- The absence of any band or signal in the range of though N-oxide is a minor metabolite,1,10–12) it retains 310–320 nm indicates the absence of an extra-frame- its original structure and is useful for identification. work octahedral TiO2 phase in the TS-1 sample. Conventional preparation methods for the N-oxide Small-Scale Reaction of Antipsychotic Phenothi- of general ternary amino compounds are oxidation azines with Hydrogen Peroxide Using Titano- by hydrogen peroxide or organic peroxide.13–15) The silicate as Catalyst —–— Each phenothiazine so- reaction rate with hydrogen peroxide is slow and the lution (0.1 mmol) was mixed with 0.2 M acetate yield is low, while the latter method represented by buffer (pH 3.0) and methanol (final concentration: m-chloroperbenzoic acid requires the maintenance 20%) in a test tube with a screw plug, and stirred of a low reaction temperature and purification of the with the indicated amounts of 30% hydrogen per- column chromatography system. oxide and titanosilicate in a water bath at 60°C for Hydrogen peroxide is a very attractive oxidant 1 hr. The total volume of the reaction mixtures was because it is relatively cheap and can oxidize or- 0.5 ml, although that of periciazine was increased ganic compounds with the generation of water as to 1 ml by increasing the amounts of methanol and the only theoretical by-product. Recently, many cata- buffer in order to improve its solubility. As control lysts have been developed to enhance the efficiency tubes, the drug solutions were incubated in the same of the oxidation ability of hydrogen peroxide. We acetate buffer and methanol without titanosilicate selected titanosilicate as the catalyst for oxidation and hydrogen peroxide under the same conditions. by hydrogen peroxide since the effective catalytic Prochlorperazine maleate was converted into the free ability of titanosilicate to form sulfoxide from a form to improve the solubility. An equal molar simple structural sulfide (thioether) in the presence amount of 35% hydrogen chloride (0.1 mmol) was of hydrogen peroxide has been reported.16–18) added to the reaction mixtures containing free base Titanosilicate has been used in the field of chemical type phenothiazine (pericyazine, perphenazine and industry as a catalyst for hydrogen peroxide.19) prochlorperazine). This article deals with the search for the optimal After the reactions, the reaction mixture was di- reaction conditions of reaction to form the oxide of luted with cold milli-Q water (1.5 ml) and the pH of each drug using hydrogen peroxide and titanosilicate the solution was adjusted to 10.0 with 1 M sodium in a small scale reaction (0.1 mmol). Larger amounts carbonate. The reaction mixture was vigorously of drugs (2 mmol) were then oxidized on the basis stirred with chloroform twice (1.5 ml each) for of the optimal conditions obtained, and purification 3 min. After centrifugation, the chloroform phase of the oxides formed was carried out using crystalli- was removed using a pasteur pipette, and the com- zation. bined extract was dried under a stream of N2 gas at 40°C. The residue was dissolved in methanol (HPLC grade, 1 ml), and 0.1 ml of this methanol solution MATERIALS AND METHODS was diluted to 100-fold with HPLC eluting solution, and then analyzed by HPLC. Materials —–— Chlorpromazine hydrochloride, Small-Scale Reaction of Cyclic Antidepressants promethazine hydrochloride, periciazine (synonym: with Hydrogen Peroxide Using Titanosilicate as pericyazine, propericiazine), imipramine hydrochlo- Catalyst —–— Each methanol solution of the HCl ride, and 30% hydrogen peroxide (9.88 mmol/ml) salts of cyclic antidepressants (0.1 mmol) was mixed were purchased from Wako Pure Chemical Indus- with 1 M carbonate buffer (pH 10.5) and methanol tries (Osaka, Japan). Promazine hydrochloride, (final volume: 50%) and stirred with the indicated fluphenazine dihydrochloride, trifluoperazine amounts of 30% hydrogen peroxide and titanosilicate dihydrochloride, perphenazine, prochlorperazine in a water bath at 60°C for 1 hr (total volume: dimaleate, clomipramine hydrochloride, amitrip- 0.5 ml). As control tubes, the drug solutions were tyline hydrochloride, and mianserin hydrochloride incubated in the indicated buffer and methanol with- were purchased from Sigma Chemical Co. (St. Louis, out titanosilicate and hydrogen peroxide under the MO, U.S.A.). Titanosilicate catalyst, TS-1, was same conditions. After the reaction, the reaction kindly supplied by Süd-Chemie Catalysts Japan Inc. mixture was diluted with cold milli-Q water (1.5 ml) (Tokyo, Japan). The Si/Ti molar ratio in the TS-1 and extracted with chloroform twice (1.5 ml each). used was 70, and average particle size as determined The rest of the procedure was the same as that for by scanning electron micrographs was 100–200 nm. phenothiazines described above. 398 Vol. 50 (2004) Preparation of Phenothiazine Sulfoxide —–— silane column (Mightysil RP-18, 4.6 × 250 mm, Each solid phenothiazine (2 mmol) was transferred 5 µm, Kanto Chemicals Co., Inc., Tokyo, Japan) with to an Erlenmeyer flask, and dissolved in 2 ml of the eluting solution of 67 mM phosphate buffer 20) methanol and a calculated amount (8 ml – volume (pH 3.0) - CH3CN (91 : 49, v/v) at a flow rate of of hydrogen peroxide) of 0.2 M sodium acetate 1.2 ml/min. The wavelengths of the UV detector for buffer (pH 3.0). Titanosilicate (100 mg) and the in- phenothiazine were set at 247–260 nm depending dicated amount of 30% hydrogen peroxide were on each drug as described in the Results. The wave- added. The reaction mixture (10 ml) was stirred in a length setting for the cyclic antidepressants was water bath at 60°C for 1 hr.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test
    DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Antipsychotics and the Risk of Sudden Cardiac Death
    ORIGINAL INVESTIGATION Antipsychotics and the Risk of Sudden Cardiac Death Sabine M. J. M. Straus, MD; Gyse`le S. Bleumink, MD; Jeanne P. Dieleman, PhD; Johan van der Lei, MD, PhD; Geert W. ‘t Jong, PhD; J. Herre Kingma, MD, PhD; Miriam C. J. M. Sturkenboom, PhD; Bruno H. C. Stricker, PhD Background: Antipsychotics have been associated with Results: The study population comprised 554 cases of prolongation of the corrected QT interval and sudden car- sudden cardiac death. Current use of antipsychotics was diac death. Only a few epidemiological studies have in- associated with a 3-fold increase in risk of sudden car- vestigated this association. We performed a case- diac death. The risk of sudden cardiac death was high- control study to investigate the association between use est among those using butyrophenone antipsychotics, of antipsychotics and sudden cardiac death in a well- those with a defined daily dose equivalent of more than defined community-dwelling population. 0.5 and short-term (Յ90 days) users. The association with current antipsychotic use was higher for witnessed cases Methods: We performed a population-based case-control (n=334) than for unwitnessed cases. study in the Integrated Primary Care Information (IPCI) project, a longitudinal observational database with com- Conclusions: Current use of antipsychotics in a gen- plete medical records from 150 general practitioners. All eral population is associated with an increased risk of sud- instances of death between January 1, 1995, and April 1, den cardiac death, even at a low dose and for indica- 2001, were reviewed. Sudden cardiac death was classified tions other than schizophrenia.
    [Show full text]
  • Importance of the Newer Generations Of
    Psychiatria Danubina, 2013; Vol. 25, No. 3, pp 329-333 Conference paper © Medicinska naklada - Zagreb, Croatia IMPORTANCE OF THE NEWER GENERATIONS OF ANTIPSYCHOTICS IN REDUCING SCHIZOPHRENIA HOSPITALIZATION RATES Vlado Jukić, Aleksandar Savić & Miroslav Herceg University Psychiatric Hospital Vrapče, Zagreb, Croatia SUMMARY Throughout history, given the lack of understanding of schizophrenia and lack of effective treatment options, patients were often committed to asylums and later psychiatric institutions, often for prolonged periods of time. First antipsychotic medications helped to bring about changes in approach to these patients and facilitated deinstitutionalization, and discovery of new drugs with differing side-effects profiles introduced new options in treating schizophrenia patients. Data on hospitalization of patients in University Psychiatric Hospital Vrapče from the mid-1990s, as well as data on national level, suggests a trend of drop in hospitalization of schizophrenia patients. At the same time, that period saw significant increase in a number of available newer-generations antipsychotics and the rise in their use compared to first-generation one. Although far from being the only contributing factor, seem to play an important role in continuing the trend of reducing hospitalization rates for schizophrenia patients that started with first antipsychotics. Newer antipsychotics with a more tolerable side-effects profile promote better compliance and further reduce rate of relapse and hospitalizations. No less important is the contribution of newer antipsychotics with new receptor profiles to the personalized psychopharmacotherapy approach that is in tune with emerging conceptualizations of schizophrenia as a complex syndrome with a number of separate symptom domains, whose specific combinations produce specific individual clinical presentation and in turn ask for a specific individual approach to the patient.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Studies with Lysergic Acid Diethylamide in Regressed Schizophrenics
    CHAPTER 15 _ Studies with Lysergic Acid Diethylamide in Regressed Schizophrenics By FREDERICK B. CHARAT AN, M.D. OF THE MANY studies carried out with lysergic acid diethylamide in the last 15 years, relatively few have dealt with regressed schizophrenics. Most workers have used comparatively small doses of LSD. Some gave up to 600 gamma orally. Others reported the effects of up to 500 gamma intra- muscularly, 180 gamma intravenously and 60 gamma intrathecally in small series of cases. Several investigators agreed that in chronic schizophrenics higher doses of LSD than those administered to undeteriorated schizo- phrenics and nonpsychotics have been required to produce psychic effects. Apart from the slight response of chronic schizophrenics to doses of LSD which lead to marked and characteristic effects in other subjects, tolerance to the drug seems to develop in as brief a period as three days. These differences in response to LSD pose some interesting problems. Is the lack of response in chronic schizophrenics merely an apparent one caused by their inability to communicate their inner experiences? Is it due to the development of some immune state connected with biochemical alter- ations produced during the psychosis? Is it the reflection of a metabolic difference between schizophrenics and non-schizophrenics? May it be a general manifestation of schizophrenic underresponsiveness to virtually any stress, once the chronic stagnant phase of the psychosis has been reached? Clear answers to all these questions cannot yet be given. The present investi- gation was undertaken to examine further the responses of chronic schizo- phrenics to large doses of LSD and also to observe the effect of other drugs upon this response.
    [Show full text]
  • Perphenazine-151548-PI.Pdf
    PRESCRIBING INFORMATION PERPHENAZINE Perphenazine Tablets USP 2 mg , 4 mg, 8mg, and 16 mg Antipsychotic/Antiemetic AA Pharma Inc. DATE OF REVISION: April 12, 2012 1165 Creditsone Road, Unit #1 Vaughan, Ontario L4K 4N7 Control Number: 151548 PRESCRIBING INFORMATION PERPHENAZINE Perphenazine Tablets USP 2 mg, 4 mg, 8 mg and 16 mg THERAPEUTIC CLASSIFICATION Antipsychotic/Antiemetic ACTIONS AND CLINICAL PHARMACOLOGY Perphenazine is a piperazine phenothiazine derivative with antipsychotic, antiemetic and weak sedative activity. Perphenazine has actions similar to those of other phenothiazine derivatives but appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extrapyramidal reactions. Perphenazine is well absorbed from the gastrointestinal tract. Onset of action following oral administration is 30 to 40 minutes. Duration of action is 3 to 4 hours. Perphenazine distributes to most body tissues with high concentrations being distributed into liver and spleen. Perphenazine enters the enterohepatic circulation and is excreted chiefly in the feces. INDICATIONS AND CLINICAL USE Perphenazine is indicated in the management of manifestations of psychotic disorders. It is also effective in controlling nausea and vomiting due to stimulation of the chemoreceptor trigger zone. 1 Perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. CONTRAINDICATIONS Should not be administered in the presence of circulatory collapse, altered states of consciousness or comatose states, particularly when these are due to intoxication with central depressant drugs (alcohol, hypnotics, narcotics). It is contraindicated in severely depressed patients, in the presence of blood dyscrasias, liver disease, renal insufficiency, pheochromocytoma, or in patients with severe cardiovascular disorders or a history of hypersensitivity to phenothiazine derivatives.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Phenothiazine Poisoning a Review of 48 Cases
    Refer to: Barry D, Meyskens FL Jr, Becker CE: Phenothiazine poison- ing-A review of 48 cases. Calif Med 118:1-5, Jan 1973 California Medicine THE WESTERN JOURNAL OF MEDICINE Phenothiazine Poisoning A Review of 48 Cases DANIEL BARRY, B.A., FRANK L. MEYSKENS, JR., M.D., AND CHARLES E. BECKER, M.D., San Francisco * Of 48 cases of phenothiazine poisoning that were analyzed, 34 were attributed to stuicide attempts, nine to accidental ingestion, and five to drug reactions. As outpatient treatment of schizophrenia increases, cases of over- dose with phenothiazine drugs may be expected to increase also. The prescribing of multiple phenothiazines and antidepressants is probably contributory to the occurrence of mixed drug ingestions. The symptoms and signs of phenothiazine poisoning are largely predictable if the atropine-like, alpha-blocking, quinidine-like, and extrapyramidal actions of phenothiazines are appreciated, Unexplain- able tachypnea and paradoxical miosis were noted in severe cases. In one case in the study phenothiazine intoxication was present in the newborn infant of a schizophrenic mother. PHENOTHIAZINES ARE BECOMING household drugs tionable advertising campaigns advocating phe- in Califomnia. The closing of state hospitals with nothiazines for the treatment of a wide variety the concomitant institution of mass outpatient of ailments have made these drugs generally treatment of chronic schizophrenics through com- available. The high incidence of schizophrenia munity mental health centers, and recent quesv in young adulthood and the increasing suicide From the Detoxification Unit, San Francisco General Hospital, and rate in this age group" suggest that phenothia- the Department of Clinical Pharmacology, University of California, San Francisco.
    [Show full text]
  • FOI 215-1718 Document 5
    Document 5 Case Line Listing Cases Count: 2249 Report Onset Onset Case No. Date Date State Sex Age Outcome Medicine Time Reaction 261548 04/01/2010s22(1) F 61 s22(1) Centrum Select 50+ (Vitamins and Minerals s22(1) Paraesthesia Combination) -Suspected Hypertonia Mobic (Meloxicam) -Other drug Musculoskeletal stiffness Somac (Pantoprazole) -Other drug Hypersensitivity Feeling hot Musculoskeletal chest pai 261559 05/01/2010 F 40 Blackmores Bio Magnesium (Vitamin Preparation Asthma Compound) -Suspected Singulair (Montelukast) -Other drug 261563 05/01/2010 F 72 Glucosamine NOS -Suspected Hypertension Alendro Once-Weekly (Alendronate Sodium) -Other drug Betaloc (Metoprolol Tartrate) -Other drug Caltrate (Calcium Carbonate) -Other drug Endep (Amitriptyline Hydrochloride) -Other drug Fish Oil NOS -Other drug Karvea (Irbesartan) -Other drug Pariet (Rabeprazole Sodium) -Other drug Plavix (Clopidogrel) -Other drug Pravachol (Pravastatin Sodium) -Other drug Serepax (Oxazepam) -Other drug 261583 05/01/2010 F 46 Metagenics Estrofactors (Herbal Medicines) Hypersensitivity -Suspected Rash pustular Metagenics Lipoplex (Herbal Medicines) -Suspected Ostelin 1000 (Ergocalciferol) -Other drug 261642 06/01/2010 M 32 Hydroxycut (Herbal Medicines) -Suspected Headache Tremor Vomiting Palpitations PWTRAN01 Report Printed : 22/02/2018 08:42 Page 1 of 303 Case Line Listing Cases Count: 2249 Report Onset Onset Case No. Date Date State Sex Age Outcome Medicine Time Reaction 261681 07/01/2010 M 50 Tebonin (Ginkgo Biloba) -Suspected Extrasystoles Nasonex Aqueous Nasal
    [Show full text]